Philogen SpA has withdrawn its proposed initial public offer of shares on the Milan Stock Exchange following the unexpected termination of a licensing and development contract by Bayer Schering Pharma AG, according to Philogen.
Sanofi-Aventis SA has won the agreement of Genzyme Corp’s management to acquire the US company for $74 per share in cash, plus special milestone payments if certain product goals are met. The offer is an increase from $69 per share.
E-Therapeutics Plc, which is a service company and a drug developer, is proposing to raise £17.6 million gross through a primary share offering arranged by Panmure Gordon, which is also overseeing a £3.4 million secondary offering of E-Therapeutics shares.
The non-profit Medicines for Malaria Venture and Jomaa Pharma GmbH of Germany have entered into an agreement to co-develop fosmidomycin as a component of a non-artemisinin based combination therapy for acute Plasmodium falciparum malaria.
Sinclair Pharma Plc and IS Pharma Plc, two specialist pharmaceutical companies listed in London, intend to merge through an exchange of shares, subject to certain conditions.
Researchers from Rockefeller University in New York City have shown that stem cells that leave a special niche environment to become hair follicles send signals back to the niche in order to prevent other stem cells from activating too early.
Shares of the Renovo Group Plc plunged by 75% on the London Stock Exchange on 11 February 2011 after the company announced that its first Phase 3 trial for Juvista (avotermin) for use in scare revision surgery failed to meet all clinical endpoints.
Shire Plc said sales of its pharmaceutical products exceeded $3 billion in 2010, driven by growth of its attention deficit hyperactivity disorder (ADHD) franchise and demand for an orphan drug product where a competitor drug was in short supply.
Pronova BioPharma ASA, the Norwegian omega-3 specialist, reported a decline in revenue and a loss for the quarter ended 31 December 2010 mainly because of flagging shipments to the US where inventories of Lovaza were run down.
Eli Lilly and Company Inc is enlisting the support of venture capitalists in the US and Europe to support its virtual drug development network that manages promising new molecules from candidate stage to clinical proof of concept.